Edition:
United States

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.09USD
16 Feb 2018
Change (% chg)

$-0.13 (-2.49%)
Prev Close
$5.22
Open
$5.12
Day's High
$5.23
Day's Low
$5.07
Volume
16,026
Avg. Vol
10,353
52-wk High
$12.50
52-wk Low
$4.75

Chart for

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 2.25
Market Cap(Mil.): $469.87
Shares Outstanding(Mil.): 94.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

FDA to fast track Mesoblast's cell therapy for heart failure

Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

Dec 21 2017

FDA to fast track Mesoblast's cell therapy for heart failure

Dec 21 Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

Dec 20 2017

BRIEF-Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​

* ‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​ Source text for Eikon: Further company coverage:

Dec 20 2017

BRIEF-Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment

* MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT

Dec 20 2017

BRIEF-Mesoblast Says Granted Tigenix Access To Certain Of Its Patents

* ‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​ Source text for Eikon: Further company coverage:

Dec 14 2017

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

Dec 14 2017

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

Nov 10 2017

BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment

* Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment Source text for Eikon: Further company coverage:

Sep 28 2017

BRIEF-Mesoblast posts FY loss attributable of $76.8 mln

* FY loss attributable to owners of co $76.8 million versus loss of $4.1 million Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Mesoblast completes institutional entitlement offer for capital raise

* Completes institutional entitlement offer for fully underwritten A$50.7 million capital raise

Aug 28 2017

Earnings vs. Estimates